PPAR agonists, atherogenic dyslipidemia and cardiovascular risk

Manfredi Rizzo, Dragana Nikolic, Giuseppe Montalto, Giuseppa Castellino, Maciej Banach, Dragana Nikolic, Ekaterina Ivanova, Giuseppa Castellino, Peter P. Toth, Alexader N. Orekhov, Giuseppe Montalto, Manfredi Rizzo

Risultato della ricerca: Articlepeer review

8 Citazioni (Scopus)

Abstract

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this review is to summarize the current evidence on PPAR agonists and their effects on atherogenic dyslipidemia and CV risk. The main findings indicate that PPAR agonists improve not only the lipid profile, but also lipoprotein subfractions associated with atherogenic dyslipidemia and other CV markers. However, future prospective studies are required to establish the long-term effects of such therapies on atherogenic lipoproteins and their benefit on CV outcomes.
Lingua originaleEnglish
pagine (da-a)894-902
Numero di pagine9
RivistaCURRENT PHARMACEUTICAL DESIGN
Volume23
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Fingerprint Entra nei temi di ricerca di 'PPAR agonists, atherogenic dyslipidemia and cardiovascular risk'. Insieme formano una fingerprint unica.

Cita questo